Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for ARDS in COVID-19
NCT04954014Phase 2Terminated
- Sponsor
- Maimónides Institute of Biomedical Research of Córdoba
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in acute respiratory distress syndrome (ARDS), coronavirus disease 2019 (COVID-19), sponsored by Maimónides Institute of Biomedical Research of Córdoba. Started Sep 2020; status: terminated.
02
Drugs
bevacizumab
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04954014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954014.